1. Home
  2. TKO vs EXAS Comparison

TKO vs EXAS Comparison

Compare TKO & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TKO
  • EXAS
  • Stock Information
  • Founded
  • TKO 1980
  • EXAS 1995
  • Country
  • TKO United States
  • EXAS United States
  • Employees
  • TKO N/A
  • EXAS N/A
  • Industry
  • TKO
  • EXAS Medical Specialities
  • Sector
  • TKO
  • EXAS Health Care
  • Exchange
  • TKO Nasdaq
  • EXAS Nasdaq
  • Market Cap
  • TKO 13.3B
  • EXAS 10.7B
  • IPO Year
  • TKO N/A
  • EXAS N/A
  • Fundamental
  • Price
  • TKO $174.99
  • EXAS $53.02
  • Analyst Decision
  • TKO Strong Buy
  • EXAS Strong Buy
  • Analyst Count
  • TKO 14
  • EXAS 20
  • Target Price
  • TKO $163.77
  • EXAS $70.68
  • AVG Volume (30 Days)
  • TKO 910.8K
  • EXAS 2.9M
  • Earning Date
  • TKO 08-07-2025
  • EXAS 07-30-2025
  • Dividend Yield
  • TKO 0.88%
  • EXAS N/A
  • EPS Growth
  • TKO N/A
  • EXAS N/A
  • EPS
  • TKO 1.17
  • EXAS N/A
  • Revenue
  • TKO $2,850,693,000.00
  • EXAS $2,828,128,000.00
  • Revenue This Year
  • TKO $61.32
  • EXAS $14.58
  • Revenue Next Year
  • TKO $24.18
  • EXAS $12.75
  • P/E Ratio
  • TKO $147.91
  • EXAS N/A
  • Revenue Growth
  • TKO 10.04
  • EXAS 11.57
  • 52 Week Low
  • TKO $102.46
  • EXAS $39.97
  • 52 Week High
  • TKO $179.09
  • EXAS $72.83
  • Technical
  • Relative Strength Index (RSI)
  • TKO 66.93
  • EXAS 45.95
  • Support Level
  • TKO $160.94
  • EXAS $51.50
  • Resistance Level
  • TKO $169.08
  • EXAS $53.30
  • Average True Range (ATR)
  • TKO 4.14
  • EXAS 1.62
  • MACD
  • TKO 1.06
  • EXAS -0.64
  • Stochastic Oscillator
  • TKO 83.27
  • EXAS 26.95

About TKO TKO Group Holdings Inc.

TKO Group Holdings Inc is a sports and sports entertainment company that operates combat sport and sports entertainment companies. It owns and manages valuable sports and entertainment intellectual property. The company distributes content and monetizes its intellectual property through four principal activities: Media Rights and Content, Live Events, Sponsorship, and Consumer Products Licensing. The company has two reportable segments, UFC and WWE. The company generates the majority of its revenue from the UFC segment. The UFC segment revenue consists of media rights fees associated with the distribution of its programming content, ticket sales, and site fees associated with the business's global live events, sponsorship, and consumer products licensing agreements of UFC-branded products.

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: